The stock of AstraZeneca Pharma India experienced a significant surge of over 4 percent on March 27, propelled by the news of the company’s successful attainment of approval from the Central Drugs Standard Control Organisation (CDSCO) for the importation, sale, and distribution of Trastuzumab deruxtecan lyophilized powder concentrate for solution for infusion 100mg, known as Enhertu.
Trastuzumab deruxtecan has been hailed as a promising treatment for adult patients grappling with unresectable or metastatic HER2-Low (IHC 1+ or IHC 2+/ISH-) breast cancer, particularly those who have undergone prior chemotherapy in the metastatic setting or have experienced disease recurrence within six months of completing adjuvant chemotherapy, as confirmed by AstraZeneca.
Moreover, the medication has also demonstrated efficacy in addressing the needs of adult patients diagnosed with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma, who have previously undergone a trastuzumab-based regimen, as detailed by the pharmaceutical company.
The approval from CDSCO signifies a significant milestone for AstraZeneca Pharma India, marking its commitment to addressing critical healthcare needs and expanding access to innovative oncology treatments within the Indian market. This development not only underscores the company’s dedication to advancing patient care but also augurs well for its future growth prospects in the pharmaceutical sector. As investors reacted positively to this news, the surge in AstraZeneca Pharma India’s shares reflects growing confidence and optimism among stakeholders regarding the company’s strategic direction and potential impact in the healthcare landscape.
AstraZeneca Pharma announced, ‘The receipt of this permission paves the way for the launch of Trastuzumab deruxtecan lyophilized powder for concentrate for solution for infusion 100mg (Enhertu) in India for the specified additional indications, subject to the receipt of related statutory approvals, if any.’
As of 10:27 am, AstraZeneca Pharma’s shares were being traded at Rs 5,204.70 on the National Stock Exchange (NSE), reflecting a 2.6 percent surge from the previous closing price. Over the course of the past year, the stock has exhibited an impressive growth trajectory, surging by 57 percent. This noteworthy performance has surpassed the benchmark Nifty 50 index, which has seen a 30 percent increase during the corresponding period.
Disclaimer: The information provided by Bystox regarding stock market activity is intended for informational purposes only and should not be interpreted as investment advice. Readers are strongly advised to seek guidance from a qualified financial advisor prior to making any investment decisions.